ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18+
SponsorStratpharma AG
About this trial
Vaginal atrophy patients receiving vaginal laser therapy will be treated with daily 7-0940® following a laser session to evaluate the safety and efficacy of the product as an adjunct treatment. Clinical outcomes will be assessed using validated investigator- and patient-reported measures, with safety and symptom progression monitored throughout the study.
Eligibility criteria
Qualifiers
Diagnosed vaginal atrophy
Access to smartphone and tablet, laptop or computer
Access to a valid email address
Previously completed laser therapy session schedule
Disqualifiers
Unable to provide informed consent
Patient unable to apply topical device
Allergy or intolerance to ingredients or excipients of the formulation of studied products
Systemic hormonal or steroidal therapy started less than 30 days before baseline ( = not yet on a stable regimen)
Trial design
Treatments tested in this trial
- 7-940
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov